Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism - PubMed (original) (raw)
Comparative Study
. 2006 Dec;147(12):5641-52.
doi: 10.1210/en.2006-0541. Epub 2006 Sep 21.
Affiliations
- PMID: 16997836
- PMCID: PMC2665253
- DOI: 10.1210/en.2006-0541
Comparative Study
Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism
Shen Qu et al. Endocrinology. 2006 Dec.
Abstract
FoxO1 plays an important role in mediating the effect of insulin on hepatic metabolism. Increased FoxO1 activity is associated with reduced ability of insulin to regulate hepatic glucose production. However, the underlying mechanism and physiology remain unknown. We studied the effect of FoxO1 on the ability of insulin to regulate hepatic metabolism in normal vs. insulin-resistant liver under fed and fasting conditions. FoxO1 gain of function, as a result of adenovirus-mediated or transgenic expression, augmented hepatic gluconeogenesis, accompanied by decreased glycogen content and increased fat deposition in liver. Mice with excessive FoxO1 activity exhibited impaired glucose tolerance. Conversely, FoxO1 loss of function, caused by hepatic production of its dominant-negative variant, suppressed hepatic gluconeogenesis, resulting in enhanced glucose disposal and improved insulin sensitivity in db/db mice. FoxO1 expression becomes deregulated, culminating in increased nuclear localization and accounting for its increased transcription activity in livers of both high fat-induced obese mice and diabetic db/db mice. Increased FoxO1 activity resulted in up-regulation of hepatic peroxisome proliferator-activated receptor-gamma coactivator-1beta, fatty acid synthase, and acetyl CoA carboxylase expression, accounting for increased hepatic fat infiltration. These data indicate that hepatic FoxO1 deregulation impairs the ability of insulin to regulate hepatic metabolism, contributing to the development of hepatic steatosis and abnormal metabolism in diabetes.
Figures
Fig. 1
Effect of FoxO1 gain of function on glucose metabolism in normal mice. A, Fasting blood glucose levels. B, Fasting plasma insulin levels. C, Blood glucose profiles during GTT. D, AUC of blood glucose profiles during GTT. Blood glucose and plasma levels were determined after 16-h fasting on d 4 after vector administration. Data in C and D were obtained on d 5. *, P < 0.05 vs. controls. NS, Not significant.
Fig. 2
Effect of FoxO1 gain of function on hepatic gluconeogenic expression. Mice were killed after 16-h fasting 6 d after hepatic FoxO1 expression. Liver tissue was collected for preparation of total hepatic RNA. The relative hepatic mRNA levels of G6Pase (A) and PEPCK (B) were determined by real-time RT-PCR using _β_-actin mRNA as control. Hepatic nuclear proteins were subjected to immunoblot analysis using anti-FoxO1, anti-GK, and antiactin antibodies, respectively. The relative levels of hepatic FoxO1 protein were compared between FoxO1 vector- vs. control vector-treated mice (C). Representative immunoblots were shown in D. *, P < 0.05.
Fig. 3
Hepatic glycogen and lipid content. Hepatic glycogen (A) and lipid (B) contents, defined as milligram of glycogen or triglyceride per gram of total liver protein, were determined as described in Materials and Methods. Sections of liver of mock- (C), FoxO1 vector- (D), and LacZ (E) vector-treated mice were examined histologically after Oil red O staining. Fasting plasma ALT (F) and AST (G) levels were determined at d 6 after vector administration. *, P < 0.01. Bar, 100 _μ_m.
Fig. 4
Impact of FoxO1 on hepatic lipogenic expression. Mice were killed after 16-h fasting after 6 d of hepatic FoxO1 production in normal CD-1 mice. Hepatic mRNA levels of FAS (A), ACC (B), and SREBP-1c (C) were determined using β_-actin mRNA as control. Hepatic protein levels of SREBP-1c (D) and PGC-1_β (E) were determined by semiquantitative immunoblot analysis. Cytosolic (molecular mass, 125 kDa) and nuclear (molecular mass, 68 kDa) SREBP-1 levels were coordinately produced. Quantitative data show hepatic levels of cytosolic SREBP-1c proteins. In addition, HepG2 cells were transduced with FoxO1 and LacZ vector at an MOI of 100 pfu/cell in 6-well plates. After 24 h incubation, PGC-1_β_ protein levels (F) were determined. *, P < 0.05. NS, Not significant.
Fig. 5
Hyperinsulinemic/euglycemic clamp studies. A, GIR. B, HGP rate. Three groups of CD-1 mice (n = 6, mean body weight, 33.7 ± 2.5 g) were mock treated or treated with FoxO1 or LacZ vector. Animals were cannulated on d 3 after treatment. After 1 d of recovery, animals were subjected to hyperinsulinemic/euglycemic clamping for the determination of GIR and HGP as described in Materials and Methods. *, P < 0.01.
Fig. 6
Effect of FoxO1 on hepatic metabolism in FoxO1S253A transgenic mice. FoxO1S253A transgenic mice (Foxo1-tg, n = 5) at 8 months of age and control littermates (Ctrl, n = 7) were killed after 16-h fasting. Liver tissues were studied for hepatic fat content by staining with Oil red O (A and B) and quantifying hepatic TG content (C). Hepatic protein levels of SREBP-1c (D) and PGC-1_β_ (E) were quantified by a semiquantitative immunoblot assay. Quantitative data show hepatic abundance of cytosolic SREBP-1c proteins because cytosolic and nuclear SREBP-1 levels were coordinately expressed. *, P < 0.05. Bar, 50 _μ_m.
Fig. 7
FoxO1 expression in high-fat diet-induced obese mice. C57 BL/6J mice at 6 wk of age were fed a high-fat diet (n = 6) or regular chow (n = 6) for 2 months. A, Body weight. B, Fasting blood glucose levels. C, Fasting plasma insulin levels. D, Blood glucose profiles during GTT. E, Nuclear and total FoxO1 protein levels. F, Immunoblot of cytoplasmic vs. nuclear FoxO1 protein. G, FoxO1 mRNA levels. Total liver RNA was prepared for the determination of FoxO1 mRNA levels by semiquantitative RT-PCR using _β_-actin mRNA as control. Fasting blood glucose and plasma insulin levels were determined after a 16-h fast. *, P < 0.05; **, P < 0.001.
Fig. 8
Effect of FoxO1 loss of function on glucose metabolism in db/db mice. A, Blood glucose profiles during GTT. B, AUC of blood glucose profiles during GTT. C, Changes in blood glucose levels in response to insulin tolerance test. D, Fasting plasma insulin levels. Data in A and B were obtained on d 4 after vector administration. Insulin tolerance test was performed on d 5 after vector administration. For blood glucose levels higher than 500 mg/dl, aliquots of 5-_μ_l freshly collected tail-vein blood samples were mixed with 5 _μ_l PBS buffer before blood glucose levels were immediately measured by glucometer. *, P < 0.05; **, P < 0.001.
Fig. 9
Hepatic FoxO1 expression in fed and fasting states. Male C57BL/6J mice (6 months old on regular chow) were fasted for 24 h (n = 3) or fed ad libitum (n = 4). Liver tissue was collected from killed mice for the preparation of liver protein extracts. Aliquots of 20 _μ_g liver proteins were subjected to 4–20% gradient SDS-PAGE. Hepatic abundance of FoxO1 (A) was determined by semiquantitative immunoblot assay. Hepatic FoxO1 mRNA levels (B) were determined by real-time RT-PCR using _β_-actin mRNA as control. Hepatic FoxO1 subcellular distribution in fasting (C–E) and nonfasting (F–H) states was examined by immunohistochemistry using anti-FoxO1 antibody. Arrows mark FoxO1-colocalized nuclei (E). Bar, 20 _μ_m. *, P < 0.001.
Similar articles
- Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice.
Altomonte J, Richter A, Harbaran S, Suriawinata J, Nakae J, Thung SN, Meseck M, Accili D, Dong H. Altomonte J, et al. Am J Physiol Endocrinol Metab. 2003 Oct;285(4):E718-28. doi: 10.1152/ajpendo.00156.2003. Epub 2003 Jun 3. Am J Physiol Endocrinol Metab. 2003. PMID: 12783775 - Pancreatic-derived factor promotes lipogenesis in the mouse liver: role of the Forkhead box 1 signaling pathway.
Li J, Chi Y, Wang C, Wu J, Yang H, Zhang D, Zhu Y, Wang N, Yang J, Guan Y. Li J, et al. Hepatology. 2011 Jun;53(6):1906-16. doi: 10.1002/hep.24295. Epub 2011 May 2. Hepatology. 2011. PMID: 21412813 - MicroRNA-21 regulates hepatic glucose metabolism by targeting FOXO1.
Luo A, Yan H, Liang J, Du C, Zhao X, Sun L, Chen Y. Luo A, et al. Gene. 2017 Sep 5;627:194-201. doi: 10.1016/j.gene.2017.06.024. Epub 2017 Jun 13. Gene. 2017. PMID: 28627440 - FoxO1 integrates insulin signaling to VLDL production.
Kamagate A, Dong HH. Kamagate A, et al. Cell Cycle. 2008 Oct;7(20):3162-70. doi: 10.4161/cc.7.20.6882. Epub 2008 Oct 27. Cell Cycle. 2008. PMID: 18927507 Free PMC article. Review. - Targeting FoxO1 for hypertriglyceridemia.
Kim DH, Zhang T, Ringquist S, Dong HH. Kim DH, et al. Curr Drug Targets. 2011 Aug;12(9):1245-55. doi: 10.2174/138945011796150262. Curr Drug Targets. 2011. PMID: 21443465 Review.
Cited by
- Menin orchestrates hepatic glucose and fatty acid uptake via deploying the cellular translocation of SIRT1 and PPARγ.
Liu T, Li R, Sun L, Xu Z, Wang S, Zhou J, Wu X, Shi K. Liu T, et al. Cell Biosci. 2023 Sep 22;13(1):175. doi: 10.1186/s13578-023-01119-y. Cell Biosci. 2023. PMID: 37740216 Free PMC article. - Molecular Genetics of Abnormal Redox Homeostasis in Type 2 Diabetes Mellitus.
Azarova I, Polonikov A, Klyosova E. Azarova I, et al. Int J Mol Sci. 2023 Mar 1;24(5):4738. doi: 10.3390/ijms24054738. Int J Mol Sci. 2023. PMID: 36902173 Free PMC article. Review. - A nexus of lipid and _O-_Glcnac metabolism in physiology and disease.
Lockridge A, Hanover JA. Lockridge A, et al. Front Endocrinol (Lausanne). 2022 Aug 30;13:943576. doi: 10.3389/fendo.2022.943576. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36111295 Free PMC article. Review. - Myeloid FoxO1 depletion attenuates hepatic inflammation and prevents nonalcoholic steatohepatitis.
Lee S, Usman TO, Yamauchi J, Chhetri G, Wang X, Coudriet GM, Zhu C, Gao J, McConnell R, Krantz K, Rajasundaram D, Singh S, Piganelli J, Ostrowska A, Soto-Gutierrez A, Monga SP, Singhi AD, Muzumdar R, Tsung A, Dong HH. Lee S, et al. J Clin Invest. 2022 Jul 15;132(14):e154333. doi: 10.1172/JCI154333. J Clin Invest. 2022. PMID: 35700043 Free PMC article. - Menin regulates lipid deposition in mouse hepatocytes via interacting with transcription factor FoxO1.
Wang S, Liu T, Sun L, Du H, Xu Z, Li R, Yu Y, Mao Y, Shi K. Wang S, et al. Mol Cell Biochem. 2022 May;477(5):1555-1568. doi: 10.1007/s11010-022-04392-6. Epub 2022 Feb 19. Mol Cell Biochem. 2022. PMID: 35182330
References
- Pilkis SJ, Granner DK. Molecular physiology of the regulation of hepatic gluconeogenesis and glycogenolysis. Annu Rev Physiol. 1992;54:885–909. - PubMed
- Giaccari A, Morviducci L, Pastore L, Zorretta D, Sbraccia P, Maroccia E, Buongiorno A, Tamburrano G. Relative contribution of glycogenolysis and gluconeogenesis to hepatic glucose production in control and diabetic rats. A re-examination in the presence of euglyceamia. Diabetologia. 1998;41:307–314. - PubMed
- Boden G, Chen X, Stein TP. Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus. Am J Physiol Endocrinol Metab. 2001;280:E23–E30. - PubMed
- Kaestner KH, Knochel W, Martinez DE. Unified nomenclature for the winged helix/forkhead transcription factors. Gene Dev. 2000;14:142–146. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous